Medicina
Departamento
University of Regensburg
Ratisbona, AlemaniaPublicaciones en colaboración con investigadores/as de University of Regensburg (19)
2024
-
Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)
Advances in Therapy, Vol. 41, Núm. 9, pp. 3645-3663
-
Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE
Advances in Therapy, Vol. 41, Núm. 3, pp. 1103-1119
-
Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE
Pulmonary Circulation, Vol. 14, Núm. 3
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Bone Marrow Transplantation, Vol. 58, Núm. 10, pp. 1084-1088
2020
-
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
European Urology
-
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees
European Urology, Vol. 77, Núm. 2, pp. 223-250
-
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
Journal of cardiovascular pharmacology, Vol. 76, Núm. 1, pp. 4-22
-
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
Cardiac Failure Review, Vol. 6
2019
-
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727
-
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Nature Communications, Vol. 10, Núm. 1
-
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification
Human Mutation, Vol. 40, Núm. 9, pp. 1557-1578
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
-
Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study
American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687
2010
-
Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1809-1815
-
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database
Journal of Rheumatology, Vol. 37, Núm. 7, pp. 1488-1501
2006
-
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial
British Journal of Cancer, Vol. 94, Núm. 8, pp. 1122-1129
2005
-
Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results
Nephrology Dialysis Transplantation, Vol. 20, Núm. 5, pp. 968-973